Skip to content
Sign in
Health · Europe

Moderna and Merck cancer vaccine data reveal nears Madrid congress

Moderna and Merck are expected to reveal cancer-vaccine data within days, as the European Society for Medical Oncology Congress takes place in Madrid. STAT reporters Adam Feuerstein and Andrew Joseph are covering the congress, while separate headlines from Investors.com, Nacionale and MarketWatch also flag the approaching data disclosure.

AI-assisted synthesis · Based on 5 outlets' reporting · Article text read from 2 of 5 outletsHow it's made

View timeline · 10 entries
5 outletsLatest reporting 3 min read
Coverage: Mostly CenterL 0 · C 2 · R 1 · 2 unrated
File photo
Photo: Fletcher / Wikimedia Commons (CC BY 4.0)

What happened

Key facts

  • Moderna is about to release the trial results for its cancer vaccine.
  • Data on Moderna and Merck’s cancer vaccine are expected to be revealed within days.
  • The European Society for Medical Oncology Congress is taking place in Madrid.
  • STAT senior writer Adam Feuerstein is reporting from the congress.
  • Andrew Joseph is joining Feuerstein’s coverage.

The brief

Moderna and Merck are expected to disclose data on their cancer vaccine within days, while the European Society for Medical Oncology Congress is taking place in Madrid.

The approaching disclosure is the central event: STAT’s preview places it alongside coverage from the congress, and separate headlines from Investors.com, Nacionale and MarketWatch also point to the pending data release. STAT senior writer Adam Feuerstein is reporting from Madrid, with colleague Andrew Joseph joining his coverage.

Feuerstein traveled from Boston, and Joseph arrived from London. Their reporting is tied to the European Society for Medical Oncology Congress, where the forthcoming vaccine data is drawing attention from biotech readers. The sources describe the vaccine as a collaboration between Moderna and Merck. The data is expected within days, but no results are given in the coverage.

The central near-term development, therefore, is the disclosure itself; the reporting does not establish what the findings will show or how they may affect treatment. The outlets emphasize different aspects of the same approaching announcement. STAT focuses on the congress coverage and the expected timing.

Nacionale’s headline also says Moderna and Merck are expected to reveal cancer-vaccine data. MarketWatch frames the forthcoming trial results as important, saying a lot is riding on them, without specifying in its headline what those stakes are.

Investors.com introduces a separate market-related claim: its headline says Moderna’s stock fell 20% on reportedly leaked cancer-vaccine data. That wording attributes the information to a reported leak, rather than presenting its contents as confirmed.

The headline does not identify the data or explain the reported stock movement, so it cannot establish the leak’s accuracy or a causal connection beyond its own phrasing. Feuerstein’s coverage also includes his work as co-host of The Readout Loud and author of Adam’s Biotech Scorecard.

The congress reporting brings his biotech coverage together with Joseph’s contribution from Madrid, while the expected announcement keeps attention on the Moderna-Merck vaccine data. The immediate questions are what the companies disclose and how the reported leak relates, if at all, to the forthcoming release.

The available details do not establish trial results, the contents of any leak, or a specific consequence for patients or the companies. Until the disclosure, the reported 20% stock move and the anticipated data remain distinct claims rather than confirmed trial findings.

Why it matters

  • People with cancer could have a direct stake in the Moderna-Merck vaccine data because the announcement concerns a cancer treatment; the sources provide no patient numbers or results.
  • Moderna and Merck are the named companies behind the vaccine collaboration, and the expected disclosure is the concrete event that could clarify the data’s findings.
  • Investors.com’s headline reports a 20% Moderna stock decline linked to reportedly leaked data, indicating a potential market cost while leaving the leak’s contents unconfirmed.
  • The European Society for Medical Oncology Congress in Madrid is the setting for the reporting as the companies’ data disclosure approaches.

What to watch next

  • Whether Moderna and Merck disclose their cancer-vaccine data within the reported window of days.
  • What trial findings the companies reveal.
  • Whether any information described as reportedly leaked by Investors.com matches the forthcoming disclosure.
  • Whether the congress coverage from Adam Feuerstein and Andrew Joseph reports additional details about the data.

How it's being covered

Coverage analysisShow details
5 source articles · 5 unique outlets
Outlet political mix: Mostly Center· 2 Center · 1 Right · 2 unrated
Where the outlets are based: Unknown 60% · US/Canada 20% · Other 20%
Outlet political mix
Mostly Center
Left
Center
Right
0 outlets
2 outlets
1 outlet
The marker shows coverage balance: each unique outlet counts once. 2 unrated outlets are not included.
Geography
Where the outlets covering this story are based.
5 unique outletsDominant coverage: US/Canada
How we measure coverage

How outlets' accounts compare

2 framing differences · 4 uncorroborated claims · 3 information gaps
The reports repeat the same account with different emphasis; its central claims are not independently confirmed in the reporting Updat3 read.Compared across 2 reports whose article text Updat3 read; 3 other outlets were checked by headline only.
Framing / emphasis differences
Sources emphasise different angles, actors or consequences of the same reporting.
  • STAT centers its coverage on the congress and the expected data announcement; Investors.com instead foregrounds its headline claim of a 20% stock decline linked to reportedly leaked data.
  • MarketWatch characterizes the forthcoming trial results as carrying substantial stakes, while STAT emphasizes their timing and congress coverage.
Updat3: These are differences of emphasis, not disputes about what is reported. They do not show that the reported claims are true.
One-sided or uncorroborated claims
Claims that come from one party or one source family and are not independently corroborated.
  • Investors.com links a reported 20% stock decline to reportedly leaked data in its headline; the other sources do not make that claim.
  • Investors.com describes the data as reportedly leaked, but the supplied coverage does not establish the leak’s contents or confirm that the reported data are accurate.
  • Investors.com’s headline says Moderna fell 20% on reportedly leaked cancer-vaccine data.
  • MarketWatch’s headline says a lot is riding on the cancer-vaccine trial results.
Updat3: Not independently corroborated yet — treat as a claim, not an established fact.
Not established by the reporting
Information the available reporting does not contain or confirm. This is a gap, not a disagreement.
  • The coverage does not provide the vaccine’s trial design, patient population, efficacy or safety results, or a planned disclosure date.
  • It does not identify what specific data were reportedly leaked or document how the reported leak relates to the forthcoming release.
  • The trial results and their implications are not stated.
Updat3: Updat3 cannot conclude anything about this from the current sources.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. In 2005, researchers Katalin Karikó and Drew Weissman published work showing that modified nucleosides could reduce unwanted inflammatory responses to synthetic mRNA, helping make therapeutic mRNA more practical.
    Background · from our historical context
  2. Moderna was founded to develop medicines based on messenger RNA.
    Background · compiled and fact-checked by Updat3
  3. Pembrolizumab, marketed as Keytruda, is an immune-checkpoint inhibitor: the FDA first approved it for melanoma in 2014, and it later became a standard treatment across several cancers.
    Background · from our historical context
  4. Moderna and Merck began collaborating to develop personalized cancer vaccines.
    Background · compiled and fact-checked by Updat3
  5. Sahin, Türeci and colleagues reported clinical studies of individualized neoantigen vaccines in melanoma.
    Background · compiled and fact-checked by Updat3
  6. Moderna and Merck expanded their collaboration on personalized cancer vaccines.
    Background · compiled and fact-checked by Updat3
  7. In June 2022, Moderna and Merck announced a phase 3 trial of V940 with pembrolizumab for high-risk melanoma after surgery.
    Background · from our historical context
  8. In February 2023, the U.S. Food and Drug Administration had granted the vaccine breakthrough-therapy designation for melanoma.
    Background · from our historical context
  9. Moderna and Merck presented initial KEYNOTE-942 results at the American Association for Cancer Research meeting.
    Background · compiled and fact-checked by Updat3
  10. The companies reported that the combination reduced the risk of recurrence or death; the findings were subsequently published in *The Lancet* on April 18, 2023.
    Background · from our historical context

How we got here

The closest precedent for the data expected at the Madrid congress was the phase 2b KEYNOTE-942 trial, whose first results Moderna and Merck presented at the American Association for Cancer Research meeting on April 16, 2023.

The companies reported that the combination reduced the risk of recurrence or death; the findings were subsequently published in *The Lancet* on April 18, 2023. In February 2023, the U.S. Food and Drug Administration had granted the vaccine breakthrough-therapy designation for melanoma.

Original sources

1 of 5 articles · Global · Show all

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.